Institution
Belarusian State Medical University
Education•Minsk, Belarus•
About: Belarusian State Medical University is a education organization based out in Minsk, Belarus. It is known for research contribution in the topics: Population & Medicine. The organization has 536 authors who have published 513 publications receiving 4635 citations.
Topics: Population, Medicine, Gene, Optical flow, Alpha helix
Papers published on a yearly basis
Papers
More filters
••
University College London1, Great Ormond Street Hospital for Children NHS Foundation Trust2, Boston Children's Hospital3, University of Montpellier4, Iran University of Medical Sciences5, University of Zielona Góra6, Katholieke Universiteit Leuven7, King Edward Memorial Hospital8, Cairo University9, University of Padua10, Radboud University Nijmegen11, Charité12, Utrecht University13, University of Queensland14, Pamukkale University15, Lund University16, Catholic University of the Sacred Heart17, King Abdulaziz University18, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico19, Belarusian State Medical University20, Erciyes University21, Çukurova University22, Vilnius University23, Royal Brisbane and Women's Hospital24, University Hospital Centre Zagreb25, Hannover Medical School26
TL;DR: Long-term follow-up from this large dRTA cohort shows an overall favourable outcome with normal adult height for most and no patient with CKD Stage 5, however, 82% of adult patients have CKD Stages 2-4, and importance of adequate metabolic control was highlighted by better growth and renal function.
Abstract: Background: Primary distal renal tubular acidosis (dRTA) is a rare disorder, and we aimed to gather data on treatment and long-term outcome. / Methods: We contacted paediatric and adult nephrologists through European professional organizations. Responding clinicians entered demographic, biochemical, genetic and clinical data in an online form. / Results: Adequate data were collected on 340 patients (29 countries, female 52%). Mutation testing had been performed on 206 patients (61%); pathogenic mutations were identified in 170 patients (83%). The median (range) presentation age was 0.5 (0–54) years and age at last follow-up was 11.0 (0–70.0) years. Adult height was slightly below average with a mean (SD score) of −0.57 (±1.16). There was an increased prevalence of chronic kidney disease (CKD) Stage ≥2 in children (35%) and adults (82%). Nephrocalcinosis was reported in 88%. Nephrolithiasis was more common with SLC4A1 mutations (42% versus 21%). Thirty-six percent had hearing loss, particularly in ATP6V1B1 (88%). The median (interquartile range) prescribed dose of alkali (mEq/kg/day) was 1.9 (1.2–3.3). Adequate metabolic control (normal plasma bicarbonate and normocalciuria) was achieved in 158 patients (51%), more commonly in countries with higher gross domestic product (67% versus 23%), and was associated with higher height and estimated glomerular filtration rate. / Conclusion: Long-term follow-up from this large dRTA cohort shows an overall favourable outcome with normal adult height for most and no patient with CKD Stage 5. However, 82% of adult patients have CKD Stages 2–4. Importance of adequate metabolic control was highlighted by better growth and renal function but was achieved in only half of patients.
68 citations
••
University College London1, Chelsea and Westminster Hospital NHS Foundation Trust2, Gomel State Medical University3, University of Sarajevo4, University Hospitals of Leicester NHS Trust5, Western General Hospital6, Belarusian State Medical University7, St James's University Hospital8, Medical University of Białystok9, Karolinska University Hospital10, University of Catania11, Innsbruck Medical University12, University of Barcelona13, University of Bonn14, French Institute of Health and Medical Research15, Paris Diderot University16
TL;DR: Testing rates in well-established HIV ICs remained low across Europe, despite high prevalence rates, reflecting missed opportunities for earlier HIV diagnosis and care.
Abstract: European guidelines recommend the routine offer of an HIV test in patients with a number of AIDS-defining and non-AIDS conditions believed to share an association with HIV; so called indicator conditions (IC). Adherence with this guidance across Europe is not known. We audited HIV testing behaviour in patients accessing care for a number of ICs. Participating centres reviewed the case notes of either 100 patients or of all consecutive patients in one year, presenting for each of the following ICs: tuberculosis, non-Hodgkins lymphoma, anal and cervical cancer, hepatitis B and C and oesophageal candidiasis. Observed HIV-positive rates were applied by region and IC to estimate the number of HIV diagnoses potentially missed. Outcomes examined were: HIV test rate (% of total patients with IC), HIV test accepted (% of tests performed/% of tests offered) and new HIV diagnosis rate (%). There were 49 audits from 23 centres, representing 7037 patients. The median test rate across audits was 72% (IQR 32-97), lowest in Northern Europe (median 44%, IQR 22-68%) and highest in Eastern Europe (median 99%, IQR 86-100). Uptake of testing was close to 100% in all regions. The median HIV+ rate was 0.9% (IQR 0.0-4.9), with 29 audits (60.4%) having an HIV+ rate >0.1%. After adjustment, there were no differences between regions of Europe in the proportion with >0.1% testing positive (global p = 0.14). A total of 113 patients tested HIV+. Applying the observed rates of testing HIV+ within individual ICs and regions to all persons presenting with an IC suggested that 105 diagnoses were potentially missed. Testing rates in well-established HIV ICs remained low across Europe, despite high prevalence rates, reflecting missed opportunities for earlier HIV diagnosis and care. Significant numbers may have had an opportunity for HIV diagnosis if all persons included in IC audits had been tested.
67 citations
••
Medical University of Warsaw1, Centers for Disease Control and Prevention2, University of Zagreb3, Ege University4, Charles University in Prague5, University of Belgrade6, Vilnius University7, University of Sarajevo8, National and Kapodistrian University of Athens9, Belarusian State Medical University10
TL;DR: The shortage of resources is evident and the impact on HIV care inevitable, and non-governmental organizations should prepare for operating under minimal medical resources with the aim to secure retention on ART.
63 citations
••
TL;DR: T1D patients have low BMD and elevated prevalence of asymptomatic VFx, which is associated with the presence of T1D independently of BMD, and age, diabetes duration, age at diabetes manifestation, glycosylated hemoglobin, Z-LS,Z-FN, and the prevalence of chronic complications were similar for patients with and without VFX.
Abstract: OBJECTIVE Several studies showed low bone mineral density (BMD) and elevated risk of symptomatic fractures in patients with type 1 diabetes (T1D). To our knowledge, there has been no investigation on the prevalence of asymptomatic vertebral fractures (VFx) in T1D. In the current study, we assessed BMD and the prevalence of VFx in T1D. RESEARCH DESIGN AND METHODS We evaluated 82 T1D patients (26 males and 56 females, aged 31.1 ± 8.6 years, BMI 23.5 ± 3.3 kg/m 2 , disease duration 12.8 ± 8.3 years) and 82 controls (22 females and 60 males, aged 32.9 ± 5.8 years, BMI 23.9 ± 4.8 kg/m 2 ). Spinal and femoral BMD (as Z-score, Z-LS and Z-FN, respectively) and the prevalence of VFx were evaluated by dual X-ray absorptiometry. RESULTS T1D patients had lower Z-LS and Z-FN than controls (−0.55 ± 1.3 vs. 0.35 ± 1.0, P P P = 0.002). Age, diabetes duration, age at diabetes manifestation, glycosylated hemoglobin, Z-LS, Z-FN, and the prevalence of chronic complications were similar for patients with and without VFx. In the logistic regression analysis, the presence of VFx was associated with the presence of T1D but not with lumbar spine BMD. Whereas moderate or severe VFx was associated with low lumbar spine BMD in the whole combined group of T1D patients and controls, there was no association between moderate or severe VFx and lumbar spine BMD in the T1D group. CONCLUSIONS T1D patients have low BMD and elevated prevalence of asymptomatic VFx, which is associated with the presence of T1D independently of BMD.
63 citations
••
TL;DR: It is shown for the first time that c-Myc binds to the MGMT promoter with consequent recruitment of DNA (cytosine-5)-methyltransferase 3A, regulating the levels of MG MT promoter methylation.
Abstract: Glycogen synthase kinase 3β (GSK3β) is a serine/threonine protein kinase involved in human cancers including glioblastoma. We have previously demonstrated that GSK3β inhibition enhances temozolomide effect in glioma cells. In this report, we investigated the molecular mechanisms of sensitization of glioblastoma cells to temozolomide by GSK3β inhibition, focusing on O(6)-methylguanine DNA methyltransferase (MGMT) gene silencing. Glioblastoma tissues from patients treated with the GSK3β-inhibiting drugs were subjected to immunohistochemistry and methylation-specific PCR assay. Human glioblastoma cell lines T98G, U138, U251 and U87 were treated with a small-molecule GSK3β inhibitor, AR-A014418 or GSK3β-specific small interfering RNA. The combined effect of temozolomide and AR-A014418 on cell proliferation was determined by AlamarBlue assay and an isobologram method. MGMT promoter methylation was estimated by methylation-specific PCR and MethyLight assay. MGMT gene expression was evaluated by real-time quantitative reverse transcriptase-PCR. c-Myc and DNA (cytosine-5)-methyltransferase 3A binding to the MGMT promoter was estimated by chromatin immunoprecipitation assay. GSK3β inhibition decreased phosphorylation of glycogen synthase and reduced MGMT expression and increased MGMT promoter methylation in clinical tumors. In glioblastoma cell lines, GSK3β inhibition decreased cell viability, enhanced temozolomide effect and downregulated MGMT expression with relevant changes in the methylation levels of the MGMT promoter. Here, we showed for the first time that c-Myc binds to the MGMT promoter with consequent recruitment of DNA (cytosine-5)-methyltransferase 3A, regulating the levels of MGMT promoter methylation. The results of this study suggest that GSK3β inhibition enhances temozolomide effect by silencing MGMT expression via c-Myc-mediated promoter methylation.
62 citations
Authors
Showing all 543 results
Name | H-index | Papers | Citations |
---|---|---|---|
Hassib Narchi | 21 | 148 | 2027 |
Yuri E. Demidchik | 18 | 37 | 1117 |
Artur Mezheyeuski | 14 | 53 | 834 |
Igor Karpov | 13 | 40 | 539 |
Vladislav Victorovich Khrustalev | 11 | 51 | 349 |
Ilona Nekhayeva | 10 | 10 | 545 |
Eugene Victorovich Barkovsky | 10 | 24 | 207 |
Menizibeya O. Welcome | 9 | 46 | 394 |
Anna Vassilenko | 9 | 21 | 374 |
Aliaksandr Skrahin | 9 | 17 | 300 |
Ilya V. Pyko | 8 | 9 | 545 |
Oleg Skugarevsky | 6 | 12 | 1004 |
Anna Portyanko | 6 | 12 | 163 |
Vladimir A. Pereverzev | 5 | 16 | 75 |
Vladimir Kirillov | 5 | 9 | 60 |